|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Lederle Laboratories |
|---|---|
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002259 |
Purpose
To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.
| Condition | Intervention | Phase |
|---|---|---|
|
Sarcoma, Kaposi HIV Infections |
Drug: Mitoxantrone hydrochloride |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Dose Comparison, Efficacy Study |
| Official Title: | Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have the following:
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Concurrent Medication:
Excluded:
Patients with the following are excluded:
Prior Medication:
Excluded:
Prior Treatment:
Excluded:
Contacts and Locations
More Information
| Study ID Numbers: | 055B, 3-102 |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00002259 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Mitoxantrone Acquired Immunodeficiency Syndrome |
|
Sexually Transmitted Diseases, Viral Acquired Immunodeficiency Syndrome Sarcoma, Kaposi Immunologic Deficiency Syndromes Kaposi Sarcoma Herpesviridae Infections Virus Diseases Neoplasms, Connective and Soft Tissue Soft Tissue Sarcomas |
Malignant Mesenchymal Tumor HIV Infections Sexually Transmitted Diseases Sarcoma DNA Virus Infections Peripheral Nervous System Agents Analgesics Mitoxantrone Retroviridae Infections |
|
Sexually Transmitted Diseases, Viral Slow Virus Diseases Antineoplastic Agents Physiological Effects of Drugs Infection Neoplasms, Connective and Soft Tissue Sensory System Agents Therapeutic Uses Neoplasms, Vascular Tissue Analgesics Retroviridae Infections RNA Virus Infections Neoplasms by Histologic Type Immune System Diseases Sarcoma, Kaposi |
Acquired Immunodeficiency Syndrome Immunologic Deficiency Syndromes Pharmacologic Actions Herpesviridae Infections Virus Diseases Neoplasms HIV Infections Sexually Transmitted Diseases Lentivirus Infections Sarcoma DNA Virus Infections Peripheral Nervous System Agents Mitoxantrone Central Nervous System Agents |